An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma

Summary

Milataxel is a new taxane that may have several advantages over the currently available taxanes. The current study is designed to determine the response rate of oral Milataxel in patients with malignant Mesothelioma. The study specifically targets patients who have recurring or progressive disease following previous chemotherapy.

Timeline

Start

2008-03

Primary completion

—

Completion

—

Drugs

Indications